tradmap

LCTX Lineage Cell Therapeutics, Inc.

$1.24 +0.00%

Healthcare · Biological Products, (No Diagnostic Substances)

Lineage Cell Therapeutics, Inc. (LCTX) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $308 million. Shares last traded at $1.24, 40.9% below their 52-week high. Over the past year the stock is up 47.0%. Net profit margin is -436.5%, below the peer median of 6.3%. Revenue grew 53.2% year over year.

Market Cap
$308M
Shares Out
249.3M
EPS (TTM)
$-0.48
P/E Ratio
P/S Ratio
21.15
P/B Ratio
5.71
Dividend / Share
Dividend Yield
52-Week High
$2.09
52-Week Low
$0.83
Volume
64,978
Avg Vol (3m)
80,906.587

Performance

1W
-3.52%
1M
+1.65%
3M
-20.32%
6M
-29.83%
YTD
-25.15%
1Y
+47.02%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
40.95
SMA (50)
$1.38
SMA (200)
$1.60
Price vs SMA50
-10.76%
Price vs SMA200
-22.62%
ATR (14)
$0.07

Financials

Revenue
$15M
Net Income
$-64M
Gross Margin
56.8%
Operating Margin
-251.6%
Net Margin
-436.5%
Return on Equity
-117.9%
Return on Assets
-58.0%
Current Ratio
6.89
Debt / Equity
1.05
Revenue Growth (YoY)
+53.2%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-0.03 2026-05-12
FY 2025 $-0.28 2026-03-05
Q3 2025 $-0.28 2025-11-06
Q2 2025 $-0.15 2025-08-12
Q1 2026 $-0.02 2026-05-12
FY 2025 $-0.09 2026-03-05

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

LCTX vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers
21.15 / 5.21 med
+306% premium
Net margin vs peers
-436.5% / 6.3% med
below median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.